NeuroPace director receives 989-share stock grant

Kumar Rakhi reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Kumar Rakhi reported acquisition or exercise transactions in this Form 4 filing.

NeuroPace Inc director Rakhi Kumar received a stock grant of 989 common shares, valued at $15.63 per share, as part of non-employee director compensation in lieu of quarterly cash retainer fees. Following this award, Kumar directly holds a total of 23,039 NeuroPace common shares.

Insider Trade Summary

Grant/Award: 989 shares

Grant/Award 1 txn

Insider Kumar Rakhi

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	989	$15.63	$15K

Holdings After Transaction: Common Stock — 23,039 shares (Direct)

Footnotes (1)

1. F1. These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

Key Figures

Shares granted: 989 shares Grant price per share: $15.63 per share Shares owned after grant: 23,039 shares

3 metrics

Shares granted 989 shares Common Stock grant to director on 2026-06-19

Grant price per share $15.63 per share Valuation used for director stock award

Shares owned after grant 23,039 shares Director’s direct NeuroPace holdings following transaction

Key Terms

non-employee director compensation policy, quarterly retainer fees, Grant, award, or other acquisition

3 terms

non-employee director compensation policy financial

"pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees"

quarterly retainer fees financial

"in lieu of quarterly retainer fees"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NeuroPace (NPCE) director Rakhi Kumar report?

Director Rakhi Kumar reported receiving a grant of 989 NeuroPace common shares. The award was issued as part of the company’s non-employee director compensation policy, replacing quarterly cash retainer fees with stock, and increased Kumar’s direct holdings to 23,039 shares.

At what price were the NeuroPace (NPCE) shares granted to Rakhi Kumar valued?

The 989 NeuroPace common shares granted to director Rakhi Kumar were valued at $15.63 per share. This valuation reflects the grant price used for the non-employee director compensation award issued in lieu of the regular quarterly cash retainer fees.

How many NeuroPace (NPCE) shares does Rakhi Kumar own after this Form 4 transaction?

After receiving the 989-share stock grant, director Rakhi Kumar directly owns 23,039 NeuroPace common shares. This total reflects the updated direct ownership position reported in the Form 4, following issuance under the non-employee director compensation policy.

Was the NeuroPace (NPCE) Form 4 transaction a market purchase or sale?

The Form 4 shows no market purchase or sale by director Rakhi Kumar. Instead, the transaction is coded as a grant or award, reflecting shares issued as compensation under the non-employee director policy rather than an open-market trade.

Why did NeuroPace (NPCE) grant shares to Rakhi Kumar instead of paying cash fees?

The shares were issued under NeuroPace’s non-employee director compensation policy in lieu of quarterly retainer fees. This means the company compensated director Rakhi Kumar with stock rather than cash, aligning director compensation more directly with NeuroPace’s share performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Rakhi

(Last) (First) (Middle)

C/O NEUROPACE, INC.

455 N. BERNARDO AVENUE

(Street)

MOUNTAIN VIEW CALIFORNIA 94043

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/19/2026		A		989(1)	A	$15.63	23,039	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

Remarks:

	/s/ Leah Akin, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)